ATE334232T1 - Pharmakologische anwendungen von mitochondriellen dna assays - Google Patents

Pharmakologische anwendungen von mitochondriellen dna assays

Info

Publication number
ATE334232T1
ATE334232T1 AT02729732T AT02729732T ATE334232T1 AT E334232 T1 ATE334232 T1 AT E334232T1 AT 02729732 T AT02729732 T AT 02729732T AT 02729732 T AT02729732 T AT 02729732T AT E334232 T1 ATE334232 T1 AT E334232T1
Authority
AT
Austria
Prior art keywords
subject
assays
mitochondrial dna
mitochondrial
dna assay
Prior art date
Application number
AT02729732T
Other languages
English (en)
Inventor
Helene Cote
Julio Montaner
Michael V O'shaughnessy
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Application granted granted Critical
Publication of ATE334232T1 publication Critical patent/ATE334232T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT02729732T 2001-05-29 2002-05-29 Pharmakologische anwendungen von mitochondriellen dna assays ATE334232T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29352301P 2001-05-29 2001-05-29

Publications (1)

Publication Number Publication Date
ATE334232T1 true ATE334232T1 (de) 2006-08-15

Family

ID=23129427

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02729732T ATE334232T1 (de) 2001-05-29 2002-05-29 Pharmakologische anwendungen von mitochondriellen dna assays

Country Status (10)

Country Link
US (3) US20030099933A1 (de)
EP (1) EP1395681B1 (de)
JP (1) JP4105626B2 (de)
AT (1) ATE334232T1 (de)
AU (1) AU2002302272B2 (de)
CA (1) CA2416332C (de)
DE (1) DE60213406T2 (de)
ES (1) ES2269690T3 (de)
IL (1) IL159047A0 (de)
WO (1) WO2002097124A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002033128A2 (en) 2000-10-18 2002-04-25 Pharmasset Limited Multiplex quantification of nucleic acids in diseased cells
NZ543940A (en) * 2000-12-04 2008-04-30 Primagen B V Determining the ratio of genomic DNA and mtDNA or their related gene products with regards to determining the stage of an asymptomatic disease
US20050153381A1 (en) * 2002-02-14 2005-07-14 Marusich Michael F. Immunocapture of mitochondrial protein complexes
NL1021160C2 (nl) 2002-07-26 2004-01-27 Multigen Internat B V Werkwijze voor het bepalen van het kopieaantal van een nucleotidevolgorde.
EP1418241A1 (de) * 2002-11-08 2004-05-12 PrimaGen Holding B.V. Methode zur Quantifizierung des Verhältnisses zweier Nukleinsäuresequenzen
GB0708507D0 (en) 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
US8346485B2 (en) 2008-11-25 2013-01-01 Quest Diagnostics Investments Incorporated Methods and apparatuses for estimating initial target nucleic acid concentration in a sample by modeling background signal and cycle-dependent amplification efficiency of a polymerase chain reaction
JP5535571B2 (ja) * 2009-10-14 2014-07-02 日本メナード化粧品株式会社 表皮ターンオーバーの評価方法及びその用途
WO2012097849A2 (en) * 2011-01-18 2012-07-26 Merck Patent Gmbh Mitochondrial genome-restricted dna sequences
US9080205B2 (en) 2012-03-30 2015-07-14 The United States of America as represented by the Federal Bureau of Investigation, Department of Justice Quantification of human mitochondrial DNA using synthesized DNA standards
ES2482866B1 (es) * 2012-11-22 2015-05-12 Consejo Superior De Investigaciones Científicas (Csic) Método de diagnóstico y/o pronóstico de enfermedades neurodegenerativas.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01008549A (es) * 1999-02-23 2003-06-06 Pro Neuron Inc Metodos de tratamiento de desordenes mitocondriales.
WO2001035096A2 (en) * 1999-11-10 2001-05-17 Mitokor Diseases associated with altered mitochondrial function
WO2002033128A2 (en) * 2000-10-18 2002-04-25 Pharmasset Limited Multiplex quantification of nucleic acids in diseased cells

Also Published As

Publication number Publication date
JP2004532043A (ja) 2004-10-21
JP4105626B2 (ja) 2008-06-25
EP1395681A1 (de) 2004-03-10
US20110184051A1 (en) 2011-07-28
US20090053697A1 (en) 2009-02-26
DE60213406T2 (de) 2007-03-08
CA2416332C (en) 2012-11-13
WO2002097124A1 (en) 2002-12-05
EP1395681B1 (de) 2006-07-26
CA2416332A1 (en) 2002-12-05
IL159047A0 (en) 2004-05-12
DE60213406D1 (de) 2006-09-07
AU2002302272B2 (en) 2008-05-22
US20030099933A1 (en) 2003-05-29
ES2269690T3 (es) 2007-04-01

Similar Documents

Publication Publication Date Title
Gill et al. Nucleic acid isothermal amplification technologies—a review
Yang et al. Amplification, mutation, and sequencing of a six-letter synthetic genetic system
BR0308134A (pt) análise rápida das variações em um genoma
ATE542922T1 (de) 2'-terminator-assoziierte pyrophosphorolyse- aktivierte polymerisierung
ES2118593T3 (es) Analogos de nucleotidos de pteridina como sondas fluorescentes de adn.
ATE334232T1 (de) Pharmakologische anwendungen von mitochondriellen dna assays
WO2007041342A3 (en) Labeled nucleotide analogs and uses therefor
ATE416183T1 (de) Oligonukleotide mit alternierenden segmenten und deren verwendungen
BRPI0512110A (pt) multìmeros de oligonucleotìdeos imunoestimulatórios
DE69829760D1 (de) Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
ATE261984T1 (de) N-2 substituierte purine
KR960701219A (ko) 사람의 면역결핍 바이러스 타입1의 검출(Detection of Human Immunodeficiency Virus Type 1)
ATE557100T1 (de) Doppelsträngige lineare nukleinsäuresonde und deren verwendung
DE69838449D1 (de) Aminooxy-modifizierte oligonukleotide
WO2003008624A3 (en) Nucleic acid amplification using nicking agents
Cai et al. Kinetics of deoxyribonucleotide insertion and extension at abasic template lesions in different sequence contexts using HIV-1 reverse transcriptase.
BRPI0507960A (pt) métodos terapêuticos empregando precursores de óxido nìtrico
DE60038796D1 (de) Hochspezifische primer, amplifizierungsverfahren und kits
BR0109062A (pt) Inibidores de frutose-1,6-bisfosfatase de arila
DE602005022714D1 (de) Hybridisierung von pna-sonden in alkohollösungen
DE69815370D1 (de) Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen
Militello et al. A map of 5-methylcytosine residues in Trypanosoma brucei tRNA revealed by sodium bisulfite sequencing
Hall et al. Base composition profiling of human mitochondrial DNA using polymerase chain reaction and direct automated electrospray ionization mass spectrometry
Yelagandula et al. SARSeq, a robust and highly multiplexed NGS assay for parallel detection of SARS-CoV2 and other respiratory infections
Zelin et al. Adenosine is inherently favored as the branch-site RNA nucleotide in a structural context that resembles natural RNA splicing

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties